Log In
Print this Print this

Revusiran (ALN-TTRsc, SAR438714)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous formulation of an RNAi therapeutic targeting the transthyretin (TTR) gene using the GalNAc-conjugate delivery platform
Molecular Target Transthyretin (TTR)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloidotic cardiomyopathy (FAC); Treat transthyretin (TTR) cardiac amyloidosis; Treat transthyretin (TTR)-mediated amyloidosis
Regulatory Designation U.S. - Orphan Drug (Treat transthyretin (TTR)-mediated amyloidosis)
Partner Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today